These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23868194)

  • 1. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis.
    Sun F; Ladha SS; Yang L; Liu Q; Shi SX; Su N; Bomprezzi R; Shi FD
    Muscle Nerve; 2014 Apr; 49(4):487-94. PubMed ID: 23868194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy for Morvan syndrome associated with myasthenia gravis.
    Weiss M
    Muscle Nerve; 2012 Jul; 46(1):139-40. PubMed ID: 22693003
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for severe myasthenia gravis--experience from five patients.
    Lindberg C; Bokarewa M
    Acta Neurol Scand; 2010 Oct; 122(4):225-8. PubMed ID: 20199513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
    Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
    Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab in refractory myasthenia gravis: Extended prospective study results.
    Beecher G; Anderson D; Siddiqi ZA
    Muscle Nerve; 2018 Sep; 58(3):452-455. PubMed ID: 29742795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
    Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
    J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
    Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
    J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
    Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
    Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study.
    Collongues N; Casez O; Lacour A; Tranchant C; Vermersch P; de Seze J; Lebrun C
    Muscle Nerve; 2012 Nov; 46(5):687-91. PubMed ID: 22941747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
    J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
    Jonsson DI; Pirskanen R; Piehl F
    Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.